Skip to main content
. Author manuscript; available in PMC: 2015 Oct 21.
Published in final edited form as: Clin Pharmacol Ther. 2008 May 28;85(2):155–163. doi: 10.1038/clpt.2008.95

Figure 2.

Figure 2

Docetaxel clearance as a function of (a) CYP3A4*1B genotype, (b) CYP3A5*3C genotype, and (c) combined presence of the CYP3A4*1B and CYP3A5*1A alleles (haplotype CYP3A4/5*2). Each symbol represents an individual patient, and horizontal lines indicate median values. In b, the black circle represents the only individual with two copies of the CYP3A5*1A allele, and the black triangles in the CYP3A5 non-expressors represent carriers of the CYP3A4*1B allele. In c, all individuals in the group of CYP3A4/5*2 carriers had the CYP3A4*1A*1B/CYP3A5*1A*3C diplotype, and the black triangles in the group of noncarriers represent CYP3A5 expressors.